{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:33:38Z","timestamp":1771054418359,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd013100","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000}}],"reference-count":165,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013100.pub2","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T03:02:50Z","timestamp":1658113370000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms"],"prefix":"10.1002","volume":"2022","author":[{"given":"Michael W","family":"Huang","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine; University of Pennsylvania; Philadelphia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger Carl","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Community Health & Psychiatry; University of the West Indies; Mona Jamaica"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh B","family":"Jayaram","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Melbourne Neuropsychiatry Centre; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley N","family":"Caroff","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine; University of Pennsylvania; Philadelphia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0001|cit1","first-page":"21","article-title":"Electroconvulsive therapy in lorazepam non-responsive catatonia","volume":"45","author":"Girish","year":"2003","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0002|cit2","unstructured":"Kunigiri G Gill NS B GN Naimmagadda J Electroconvulsive therapy in lorazepam non-responsive catatonia 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002\u00a0"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1192\/bjp.133.2.143","article-title":"Serum calcium and magnesium in schizophrenia: relationship to clinical phenomena and neuroleptic treatment","volume":"133","author":"Alexander","year":"1978","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00004714-198308000-00002","article-title":"Serum calcium and magnesium levels in chronic schizophrenics","volume":"3","author":"Athanassenas","year":"1983","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0005|cit5","first-page":"637","article-title":"A double blind controlled study of ECT vs chlorpromazine in schizophrenia","volume":"31","author":"Bagadia","year":"1983","journal-title":"JAPI: Journal of the Association of Physicians of India"},{"issue":"3, 2","key":"10.1002\/14651858.CD013100.pub2-BIB0006|cit6","first-page":"193","article-title":"Efficacy and tolerability of risperidone in different dose levels","volume":"10","author":"Ceskova","year":"1994","journal-title":"Neuropyschopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0007|cit7","first-page":"50","article-title":"Efficacy and tolerability of risperidone in different dose levels","volume":"92","author":"Ceskova","year":"1996","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"3-4","key":"10.1002\/14651858.CD013100.pub2-BIB0008|cit8","first-page":"151","article-title":"Risperidone vs. perphenazine - a double-blind comparison and prolactin plasma levels","volume":"6","author":"Ceskova","year":"1994","journal-title":"Psychiatria Danubina"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0009|cit9","unstructured":"A clinical trial to study prevention of relapse in patients with schizophrenia receiving either flexible dose iloperidone or placebo in long-term use apps.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2010\/091\/001409"},{"issue":"5","key":"10.1002\/14651858.CD013100.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1192\/bjp.bp.108.055137","article-title":"Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis","volume":"194","author":"Cuesta","year":"2009","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0011|cit11","unstructured":"Denef P Baro F Van Lommel R Dom R Treatment of chronic psychotic patients with high doses of propericiazine 5th World Congress of Psychiatry; 1971 Nov 28-Dec 4; Mexico City 1971 262 3"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0012|cit12","unstructured":"A multicentre, double-blind, randomised trial to compare the effects of quetiapine and haloperidol treatment strategies on treatment outcomes (5077IL\/0050 ESTO) (This study was accessed for the Cochrane database on 9 April 2001 from a web-based repository of pharmaceutical industry clinical trials (www.clinicalstudyresults.org\/), which was established by the Pharmaceutical Research and Manufacturers of America but was phased out 20 December 2011.)\u00a0"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0013|cit13","unstructured":"Drummond M Knapp M Burns T Miller K Ruiz R Methodological issues in the outcomes assessment of a new, atypical antipsychotic 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21-25; Amsterdam 1996"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/(SICI)1099-176X(199803)1:1<15::AID-MHP2>3.0.CO;2-O","article-title":"Issues in the design of studies for the economic evaluation of new atypical antipsychotics: the ESTO study","volume":"1","author":"Drummond","year":"1998","journal-title":"Journal of Mental Health Policy and Economics"},{"issue":"8","key":"10.1002\/14651858.CD013100.pub2-BIB0015|cit15","first-page":"497","article-title":"Comparison of two antipsychotic drugs: chlorpromazine and clozapine","volume":"32","author":"Dick","year":"1975","journal-title":"Therapeutische Umschau. Revue Therapeutique"},{"issue":"9","key":"10.1002\/14651858.CD013100.pub2-BIB0016|cit16","first-page":"945","article-title":"Clozapine (leponex) compared with chlorpromazine - a double blind evaluation of pharmacological and clinical properties","volume":"16","author":"Ekblom","year":"1974","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"10","key":"10.1002\/14651858.CD013100.pub2-BIB0017|cit17","first-page":"1706","article-title":"Multifocal psychopharmaceutic testing (\"Multihospital trial\")","volume":"24","author":"Fischer Cornelssen","year":"1974","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0018|cit18","first-page":"8","volume-title":"Clozapin: Zweites Symposium","author":"Fischer-Cornelssen","year":"1976"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0019|cit19","first-page":"34","article-title":"An example of European multicenter trials: multispectral analysis of clozapine","volume":"12","author":"Fischer-Cornelssen","year":"1976","journal-title":"Psychopharmacology Bulletin"},{"issue":"7","key":"10.1002\/14651858.CD013100.pub2-BIB0020|cit20","first-page":"1006","article-title":"Multispectral investigation of psychotropic drugs","volume":"24","author":"Fischer-Cornelssen","year":"1974","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"10.1002\/14651858.CD013100.pub2-BIB0021|cit21","first-page":"77","article-title":"Clozapine: antipsychotic activity in treatment-resistant schizophrenics","volume":"1","author":"Honigfeld","year":"1984","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0022|cit22","first-page":"307","article-title":"Results of a comparative double-blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients","volume":"5","author":"Niskanen","year":"1974","journal-title":"Psychiatria Fennica"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0023|cit23","first-page":"21","article-title":"Comparison of therapeutic effect of clozapin and chlorpromazin","volume":"71","author":"Vencovsky","year":"1975","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"6","key":"10.1002\/14651858.CD013100.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/NMD.0000000000000652","article-title":"Neuroprotective effect of modified electroconvulsive therapy for schizophrenia: a proton magnetic resonance spectroscopy study","volume":"205","author":"Gan","year":"2017","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1600-0447.1974.tb09706.x","article-title":"Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia","volume":"50","author":"Gerlach","year":"1974","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD013100.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/08039487409097341","article-title":"Clozapin og haloperidol: Kliniske og biokemiske aspekter i skizofrenibehandlingen","volume":"28","author":"Gerlach","year":"1974","journal-title":"Nordisk Psykiatrisk Tidsskrift"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2466\/pr0.1957.3.3.561","article-title":"Effects of thorazine on Wechsler scores of adult catatonic schizophrenics","volume":"3","author":"Gilgash","year":"1957","journal-title":"Psychological Reports"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/1097-4679(196101)17:1<95::AID-JCLP2270170134>3.0.CO;2-0","article-title":"Thorazine therapy with catatonic schizophrenics in relation to Wechsler verbal and performance subtest comparison","volume":"17","author":"Gilgash","year":"1961","journal-title":"Journal of Clinical Psychology"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0029|cit29","first-page":"32","article-title":"A comparative study of modified electroconvulsive therapy for catatonic schizophrenia","volume":"21","author":"Liu","year":"2008","journal-title":"Shandong Jingshen Yixue [Shandong Archives of Psychiatry]"},{"issue":"3-4","key":"10.1002\/14651858.CD013100.pub2-BIB0030|cit30","first-page":"349","article-title":"A double blind comparison of a new benzamide compound YM 09151 with haloperidol in the treatment of schizophrenia","volume":"17","author":"Mori","year":"1989","journal-title":"Rinsho Hyoka"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0031|cit31","unstructured":"Mori A Kazamatsuri H Kaneno S Kamijima K Kariya T Murasaki M A double-blind comparison of emonapride with haloperidol in the treatment of schizophrenia 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan 1990 296"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0032|cit32","unstructured":"A multicenter, double-blind, randomized comparison of the efficacy and safety of quetiapine fumarate (Seroquel) and risperidone (Risperdal) in the treatment of patients with schizophrenia (This study was accessed for the Cochrane database on 10 March 2008 from a web-based repository of pharmaceutical industry clinical trials (www.clinicalstudyresults.org\/), which was established by the Pharmaceutical Research and Manufacturers of America but was phased out 20 December 2011.)"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0033|cit33","unstructured":"A comparison of Seroquel vs. Risperidone in schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00034905"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0034|cit34","unstructured":"Early pharmacological and psychological intervention for late prodromal states of psychosis clinicaltrials.gov\/ct2\/show\/NCT00204061"},{"issue":"12","key":"10.1002\/14651858.CD013100.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/ijcp.12493","article-title":"Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases","volume":"68","author":"Gopal","year":"2014","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0036|cit36","unstructured":"A randomized, double-blind, parallel group, comparative study of flexibly dosed paliperidone palmitate (25, 50, 75, or 100 mg eq.) administered every 4 weeks and flexibly dosed risperdal consta (25, 37.5, or 50 mg) administered every 2 weeks in subjects with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00210717"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0037|cit37","unstructured":"MK-0777 for the treatment of cognitive impairments in patients with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00505076"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0038|cit38","unstructured":"A study for patients with schizophrenia Eli Lilly and Company Clinical Trial Registry (This reference is for a study listed in the proprietary Eli Lilly Clinical Trial Registry. It was also listed secondarily and is available publicly at clinicaltrials.gov\/ct2\/show\/NCT00520923.)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013100.pub2-BIB0039|cit39","first-page":"53","article-title":"mGlu2\/3 receptor agonists \u2013 a non D2 approach to treating schizophrenia","volume":"11","author":"Kinon","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD013100.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013100.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD013100.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.schres.2010.02.679","article-title":"Ly2140023 monohydrate: an agonist at the mglu2\/3 receptor for the treatment of schizophrenia","volume":"117","author":"Kinon","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD013100.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JCP.0b013e31824ac357","article-title":"Reply to Dr Seeman\u2019s Comments on \"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrated in patients with DSM-IV schizophrenia\"","volume":"32","author":"Kinon","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-2007-1017128","article-title":"Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study","volume":"20","author":"Sarai","year":"1987","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1176\/ajp.117.11.1034","article-title":"The effect of meprobamate (miltown), RO 1-9569-12 (nitoman), and SCH-6673 (tindal) on the odour of schizophrenic sweat","volume":"118","author":"Smith","year":"1961","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013100.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-0028-1094631","article-title":"A comparative study of the longacting neuroleptics perphenazin enanthate and fluspirilene","volume":"12","author":"Tegeler","year":"1979","journal-title":"Pharmakopsychiatrie Und Neuropsychopharmakologie"},{"issue":"16","key":"10.1002\/14651858.CD013100.pub2-BIB0047|cit47","first-page":"79","article-title":"Comparative study of modified ECT treatment for schizophrenia with stuporous state","volume":"18","author":"Wang","year":"2012","journal-title":"Dangdai Yixue [China Contemporary Medicine]"},{"issue":"19","key":"10.1002\/14651858.CD013100.pub2-BIB0048|cit48","first-page":"56","article-title":"Clinical analysis of low-dose amisulpride in the treatment of stupor in schizophrenia","volume":"19","author":"Wang","year":"2016","journal-title":"Zhongguo Shiyong Shenjing Jibing Zazhi [Chinese Journal of Practical Nervous Diseases]"},{"issue":"2","key":"10.1002\/14651858.CD013100.pub2-BIB0049|cit49","first-page":"125","article-title":"A comparative study of clozapine vs risperidone on body posture balance","volume":"24","author":"Yu","year":"2005","journal-title":"Zhongguo Xinyao Yu Linchuang Zazhi [Chinese Journal of New Drugs and Clinical Remedies]"},{"issue":"5","key":"10.1002\/14651858.CD013100.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/archpsyc.1976.01770050043006","article-title":"Catatonia: a prospective clinical study","volume":"33","author":"Abrams","year":"1976","journal-title":"Archives of General Psychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD013100.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0052|cit52","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.v65n0403","article-title":"Neuroleptic malignant syndrome and atypical antipsychotic drugs","volume":"65","author":"Ananth","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0054|cit54","volume-title":"The Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1983"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"e381\u20135","DOI":"10.1097\/MJT.0000000000000311","article-title":"Amisulpride augmentation in acute catatonia","volume":"24","author":"Arora","year":"2017","journal-title":"American Journal of Therapeutics"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0056|cit56","first-page":"133","article-title":"The response of the different Leonhard subgroups of schizophrenia of psychotropic drugs","volume":"18","author":"Astrup","year":"1964","journal-title":"Folia Psychiatrica et Neurologica"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.genhosppsych.2017.06.011","article-title":"Alternative treatment strategies for catatonia: a systematic review","volume":"48","author":"Beach","year":"2017","journal-title":"General Hospital Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000118896","article-title":"The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavorable long-term course","volume":"26","author":"Beckmann","year":"1992","journal-title":"Neuropsychobiology"},{"issue":"2","key":"10.1002\/14651858.CD013100.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hup.376","article-title":"Clinical risk factors for neuroleptic malignant syndrome","volume":"17","author":"Berardi","year":"2002","journal-title":"Human Psychopharmacology"},{"issue":"7108","key":"10.1002\/14651858.CD013100.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0010-440X(97)90027-4","article-title":"Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings","volume":"38","author":"Blumer","year":"1997","journal-title":"Comprehensive Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0062|cit62","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.biopsych.2010.09.052","article-title":"A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia","volume":"69","author":"Buchanan","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0447.1996.tb09814.x","article-title":"Catatonia. I. Rating scale and standardized examination","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Journal of Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013100.pub2-BIB0066|cit66","first-page":"12","article-title":"Movement disorders associated with atypical antipsychotic drugs","volume":"63","author":"Caroff","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1176\/appi.books.9781615377176.lg02","volume-title":"Catatonia: From Psychopathology to Neurobiology","author":"Caroff","year":"2004"},{"issue":"3","key":"10.1002\/14651858.CD013100.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4088\/JCP.09m05793yel","article-title":"Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia","volume":"72","author":"Caroff","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9758\/cpn.2021.19.1.1","article-title":"Drug-induced hyperthermic syndromes in psychiatry","volume":"19","author":"Caroff","year":"2021","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013100.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10401230600614710","article-title":"Amantadine and memantine in catatonic schizophrenia","volume":"18","author":"Carroll","year":"2006","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2007-1014355","article-title":"Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses","volume":"26","author":"Ceskova","year":"1993","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/0972-6748.110955","article-title":"Clozapine responsive catatonia: a series of five cases","volume":"21","author":"Chattopadhyay","year":"2012","journal-title":"Industrial Psychiatry Journal"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/B978-0-444-53497-2.00034-6","article-title":"Other therapeutic psychiatric uses of superficial brain stimulation","volume":"116","author":"Cristancho","year":"2013","journal-title":"Handbook of Clinical Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013100.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4088\/JCP.13r08870","article-title":"Guidelines for preventing common medical complications of catatonia: case report and literature review","volume":"75","author":"Clinebell","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.psychres.2014.12.048","article-title":"Abnormal movements in first-episode, nonaffective psychosis: dyskinesias, stereotypies, and catatonic-like signs","volume":"226","author":"Compton","year":"2015","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamapsychiatry.2016.2126","article-title":"Going beyond classic descriptions to future phenomenology of schizophrenia","volume":"73","author":"Cuesta","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0078|cit78","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0079|cit79","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1"},{"issue":"6","key":"10.1002\/14651858.CD013100.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD013100.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/0269881105053313","article-title":"Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index?","volume":"19","author":"Dursun","year":"2005","journal-title":"Journal of Psychopharmacology"},{"issue":"7109","key":"10.1002\/14651858.CD013100.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD013100.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s007020170041","article-title":"Catatonia: syndrome or schizophrenia subtype? Recognition and treatment","volume":"108","author":"Fink","year":"2001","journal-title":"Journal of Neural Transmission (Vienna, Austria: 1996)"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0086|cit86","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511543777","volume-title":"Catatonia: A Clinician's Guide to Diagnosis and Treatment","author":"Fink","year":"2003"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145711001076","article-title":"A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia","volume":"15","author":"Fleischhacker","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1017\/CBO9780511576393.008","volume-title":"Electroconvulsive and Neuromodulation Therapies","author":"Gazdag","year":"2009"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archpsyc.1977.01770200085010","article-title":"Catatonic reactions to high-potency neuroleptic drugs","volume":"34","author":"Gelenberg","year":"1977","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006570.pub2","article-title":"Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses","author":"Gibson","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013100.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0093|cit93","first-page":"233","article-title":"Maximal response to electroconvulsive therapy for the treatment of catatonic symptoms","volume":"23","author":"Hatta","year":"2007","journal-title":"Journal of Electroconvulsive Therapy"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2190\/X0FF-VU7G-QQP7-L5V7","article-title":"Somatic treatment of catatonia","volume":"25","author":"Hawkins","year":"1995","journal-title":"International Journal of Psychiatry in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD013100.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0096|cit96","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available at training.cochrane.org\/handbook\/archive\/v6.1","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1097-4679(196501)21:1<65::AID-JCLP2270210122>3.0.CO;2-I","article-title":"Nurses' observation scale for inpatient evaluation: a new scale for measuring improvement in chronic schizophrenia","volume":"21","author":"Honigfeld","year":"1965","journal-title":"Journal of Clinical Psychology"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0100|cit100","volume-title":"Basic and Clinical Pharmacology","author":"Katzung","year":"2015"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0101|cit101","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"10","key":"10.1002\/14651858.CD013100.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/jamapsychiatry.2016.1976","article-title":"Phenomenology of schizophrenia and the representativeness of modern diagnostic criteria","volume":"73","author":"Kendler","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002130050603","article-title":"A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia","volume":"137","author":"King","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/9781119536604.ch4","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre","year":"2019"},{"issue":"11","key":"10.1002\/14651858.CD013100.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0106|cit106","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-7091-6371-9","volume-title":"Classification of Endogenous Psychoses and their Differential Etiology","author":"Leonhard","year":"1999"},{"issue":"2-3","key":"10.1002\/14651858.CD013100.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet\u00a0"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1176\/appi.books.9781615377176.lg11","volume-title":"Catatonia: From Psychopathology to Neurobiology","author":"Lopez-Canino","year":"2004"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0924-9338(01)00583-1","article-title":"The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia","volume":"16","author":"Lynch","year":"2001","journal-title":"European Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD013100.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.143.11.1374","article-title":"Lethal catatonia","volume":"143","author":"Mann","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0114|cit114","volume-title":"Neuroleptic Malignant Syndrome and Related Conditions","author":"Mann","year":"2003"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0033291700043300","article-title":"Disturbed voluntary motor activity in schizophrenic disorder","volume":"12","author":"Manschreck","year":"1982","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0117|cit117","first-page":"25","article-title":"An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms","volume":"62 Suppl 2","author":"Martenyi","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013100.pub2-BIB0118|cit118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007479.pub2","article-title":"Pericyazine for schizophrenia","author":"Matar","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1192\/bjp.158.3.328","article-title":"Motor, volitional and behavioural disorders in schizophrenia.\u00a02: The 'conflict of paradigms' hypothesis","volume":"158","author":"McKenna","year":"1991","journal-title":"British Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD013100.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/ajp.109.8.617","article-title":"A comparison between unidirectional current nonconvulsive electrical stimulation given with Reiter's machine, standard alternating current electro-shock (Cerletti method), and pentothal in chronic schizophrenia","volume":"109","author":"Miller","year":"1953","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0121|cit121","first-page":"35","article-title":"The use of acatinol in the treatment of stable patients with schizophrenia with predominance of behaviour disorganization and subcatatonic features","volume":"114","author":"Morozova","year":"2014","journal-title":"Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/fnl.15.38","article-title":"Catatonia as part of the psychomotor syndrome in schizophrenia","volume":"10","author":"Morrens","year":"2015","journal-title":"Future Neurology"},{"issue":"Suppl","key":"10.1002\/14651858.CD013100.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/S0007125000296931","article-title":"Clinical management of clozapine patients in relation to efficacy and side-effects","volume":"17","author":"Naber","year":"1992","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013100.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.genhosppsych.2012.01.011","article-title":"Clinical predictors of response to treatment in catatonia","volume":"34","author":"Narayanaswamy","year":"2012","journal-title":"General Hospital Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1192\/bjp.165.4.548","article-title":"Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis","volume":"165","author":"Osman","year":"1994","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0127|cit127","first-page":"57","article-title":"Clozapine in the treatment of schizophrenia patients: an international multicenter trial","volume":"10","author":"Panteleeva","year":"1987","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD013100.pub2-BIB0128|cit128","first-page":"163","article-title":"Catatonia in a university inpatient service (1985-1990)","volume":"8","author":"Pataki","year":"1992","journal-title":"Convulsive Therapy"},{"issue":"3","key":"10.1002\/14651858.CD013100.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0920-9964(99)00047-X","article-title":"Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited","volume":"40","author":"Peralta","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD013100.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0920-9964(00)00035-9","article-title":"Motor features in psychotic disorders. II. Development of diagnostic criteria for catatonia","volume":"47","author":"Peralta","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"1-3","key":"10.1002\/14651858.CD013100.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.schres.2009.12.023","article-title":"DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication","volume":"118","author":"Peralta","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/jnp.6.1.1","article-title":"Malignant catatonia","volume":"6","author":"Philbrick","year":"1994","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0019-5545.82544","article-title":"Why do we prescribe ECT to schizophrenia patients?","volume":"53","author":"Phutane","year":"2011","journal-title":"Indian Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013100.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/ebmental-2020-300151","article-title":"Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies","volume":"24","author":"Roberts","year":"2021","journal-title":"Evidence Based Mental Health"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0165-0327(93)90015-C","article-title":"ECT in the treatment of the catatonic syndrome","volume":"29","author":"Rohland","year":"1993","journal-title":"Journal of Affective Disorders"},{"issue":"3","key":"10.1002\/14651858.CD013100.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/1531-8257(199905)14:3<395::AID-MDS1002>3.0.CO;2-L","article-title":"Catatonia: re-awakening to a forgotten disorder","volume":"14","author":"Rosebush","year":"1999","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0137|cit137","first-page":"100","article-title":"Subjective side effects acutely following ECT: association of treatment modality and clinical response","volume":"2","author":"Sackeim","year":"1987","journal-title":"Convulsive Therapy"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0138|cit138","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available at training.cochrane.org\/handbook\/archive\/v6.1"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"Bioimpacts"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13643-019-1035-3","article-title":"Study-based registers reduce waste in systematic reviewing: discussion and case report","volume":"8","author":"Shokraneh","year":"2019","journal-title":"Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"sgaa061","DOI":"10.1093\/schizbullopen\/sgaa061","article-title":"Cochrane Schizophrenia Group\u2019s Study-Based Register of Randomized Controlled Trials: Development and Content Analysis","volume":"1","author":"Shokraneh","year":"2020","journal-title":"Schizophrenia Bulletin Open"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0142|cit142","unstructured":"Shokraneh F Adams CE Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis Health Information and Libraries Journal 10.1111\/hir.12366"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fpsyt.2014.00181","article-title":"A clinical review of the treatment of catatonia","volume":"5","author":"Sienaert","year":"2014","journal-title":"Frontiers in Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12888-014-0253-4","article-title":"Treatment resistant schizophrenia: a comprehensive survey of randomized controlled trials","volume":"14","author":"Sinclair","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013100.pub2-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD123456.pub2","article-title":"Electroconvulsive therapy for treatment-resistant schizophrenia","author":"Sinclair","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013100.pub2-BIB0148|cit148","first-page":"S54","article-title":"Severe and uncommon involuntary movement disorders due to psychotropic drugs","volume":"37","author":"Stubner","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0149|cit149","first-page":"237","article-title":"Double-blind clinical comparison of risperidon and haloperidol in acute schizophrenic and schizoaffective psychoses","volume":"32","author":"Svestka","year":"1990","journal-title":"Activitas Nervosa Superior"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1503\/jpn.150352","article-title":"Clozapine for the management of persistent catatonia","volume":"41","author":"Tabbane","year":"2016","journal-title":"Journal of Psychiatry and Neuroscience"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0151|cit151","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2018"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jclinepi.2004.02.018","article-title":"Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time","volume":"57","author":"Trikalinos","year":"2004","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013100.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s002130050904","article-title":"Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study","volume":"142","author":"Ungvari","year":"1999","journal-title":"Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013100.pub2-BIB0155|cit155","first-page":"131","article-title":"The pharmacological treatment of catatonia: an overview","volume":"251","author":"Ungvari","year":"2001","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD013100.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pnpbp.2004.08.007","article-title":"Schizophrenia with prominent catatonic features ('catatonic schizophrenia'): I. Demographic and clinical correlates in the chronic phase","volume":"29","author":"Ungvari","year":"2005","journal-title":"Progress in Neuropsychopharmacology & Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013100.pub2-BIB0157|cit157","first-page":"463","article-title":"Amineptine treatment of persistent catatonic symptoms in schizophrenia: a controlled study","volume":"12","author":"Ungvari","year":"2010","journal-title":"Neuropsychopharmacologia Hungarica"},{"issue":"2","key":"10.1002\/14651858.CD013100.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/schbul\/sbp105","article-title":"The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders","volume":"36","author":"Ungvari","year":"2010","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2017.08.008","article-title":"Schizophrenia with prominent catatonic features: a selective review","volume":"200","author":"Ungvari","year":"2018","journal-title":"Schizophrenia Research"},{"issue":"5-6","key":"10.1002\/14651858.CD013100.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eurpsy.2005.03.012","article-title":"The use of atypical antipsychotics in the treatment of catatonia","volume":"20","author":"Van Den Eede","year":"2005","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40263-016-0345-4","article-title":"A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study","volume":"30","author":"Weiden","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1192\/bjp.158.3.419","article-title":"Catatonia: harbinger of the neuroleptic malignant syndrome","volume":"158","author":"White","year":"1991","journal-title":"British Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD013100.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1017\/S1092852900013419","article-title":"An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome","volume":"5","author":"White","year":"2000","journal-title":"CNS Spectrums"},{"issue":"7","key":"10.1002\/14651858.CD013100.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD013100.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/NDT.S52311","article-title":"Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients","volume":"9","author":"Yoshimura","year":"2013","journal-title":"Neuropsychiatric Disease and Treatment"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T15:18:58Z","timestamp":1761232738000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013100.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":165,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013100.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]}}}